TickerFacts.

UL Solutions Inc. (ULS): Revenue

Annual figures by period end, from SEC filings.

$3.05B
Year ended 2025-12-31
$3.15B
Trailing 12 months to 2026-06-30
+6.6%
3-year compound annual growth
2022-12-31: $2.52B2023-12-31: $2.68B2024-12-31: $2.87B2025-12-31: $3.05B$3.05B
2022-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$3.05B+6.4%2026-02-19, From 2025-01-01
2024-12-31$2.87B+7.2%2026-02-19, From 2024-01-01
2023-12-31$2.68B+6.3%2026-02-19, From 2023-01-01
2022-12-31$2.52Bn/a2025-02-20, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Services-Testing Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
UL Solutions Inc. (ULS)2025-12-31$3.05B+6.4%
Medpace Holdings, Inc. (MEDP)2025-12-31$2.53B+20.0%
Charles River Laboratories International, Inc. (CRL)2025-12-27$4.02B-0.9%
Incyte Corp (INCY)2025-12-31$5.14B+21.2%
Icon PLC (ICLR)2025-12-31$8.25B+0.8%
NeoGenomics Inc (NEO)2025-12-31$727.33M+10.1%
Iqvia Holdings Inc. (IQV)2025-12-31$16.31B+5.9%
NRC Health (NRC)2025-12-31$137.39M-4.0%
MaxCyte, Inc. (MXCT)2025-12-31$33.03M-14.5%

Compare ULS, MEDP, CRL, INCY side by side · Screen every company in Services-Testing Laboratories ↗